Chinese expert consensus on intestinal microecology and management of digestive tract complications related to tumor treatment (version 2022)

Wang, Jun1; Liang, Jing2,3; He, Mingxin4; Xie, Qi2,3; Wu, Qingming4; Shen, Guanxin5; Zhu, Baoli6; Yu, Jun7,8; Yu, Li9; Tan, Xiaohua10; Wei, Lanlan10; Ren, Jun11; Lv, Youyong12; Deng, Lijuan13; Yin, Qian13; Zhou, Hao14; Wu, Wei15; Zhang, Min16; Yang, Wenyan17; Qiao, Mingqiang18,19; Shu, Rong20; Xia, Zhongjun21; Li, Zhiming21; Huang, Ziming22; Hu, Weiguo23; Wang, Liang24; Liu, Zhi25; Pi, Guoliang26; Ren, Hua27,28; Ji, Yong27,28; Liu, Zhe29; Qi, Xiaofei30,31; Chen, Peng32; Shao, Liang33; Chen, Feng34; Xu, Xiaojun35; Chen, Weiqing36; Wang, Qiang4; Guo, Zhi37

2022-12-01

10.4103/jcrt.jcrt_1444_22

Journal of Cancer Research and Therapeutics   Impact Factor & Quartile

0973-1482

1998-4138

The human gut microbiota represents a complex ecosystem that is composed of bacteria, fungi, viruses, and archaea. It affects many physiological functions including metabolism, inflammation, and the immune response. The gut microbiota also plays a role in preventing infection. Chemotherapy disrupts an organism's microbiome, increasing the risk of microbial invasive infection; therefore, restoring the gut microbiota composition is one potential strategy to reduce this risk. The gut microbiome can develop colonization resistance, in which pathogenic bacteria and other competing microorganisms are destroyed through attacks on bacterial cell walls by bacteriocins, antimicrobial peptides, and other proteins produced by symbiotic bacteria. There is also a direct way. For example, Escherichia coli colonized in the human body competes with pathogenic Escherichia coli 0157 for proline, which shows that symbiotic bacteria compete with pathogens for resources and niches, thus improving the host's ability to resist pathogenic bacteria. Increased attention has been given to the impact of microecological changes in the digestive tract on tumor treatment. After 2019, the global pandemic of novel coronavirus disease 2019 (COVID-19), the development of novel tumor-targeting drugs, immune checkpoint inhibitors, and the increased prevalence of antimicrobial resistance have posed serious challenges and threats to public health. Currently, it is becoming increasingly important to manage the adverse effects and complications after chemotherapy. Gastrointestinal reactions are a common clinical presentation in patients with solid and hematologic tumors after chemotherapy, which increases the treatment risks of patients and affects treatment efficacy and prognosis. Gastrointestinal symptoms after chemotherapy range from nausea, vomiting, and anorexia to severe oral and intestinal mucositis, abdominal pain, diarrhea, and constipation, which are often closely associated with the dose and toxicity of chemotherapeutic drugs. It is particularly important to profile the gastrointestinal microecological flora and monitor the impact of antibiotics in older patients, low immune function, neutropenia, and bone marrow suppression, especially in complex clinical situations involving special pathogenic microbial infections (such as clostridioides difficile, multidrug-resistant Escherichia coli, carbapenem-resistant bacteria, and norovirus).

Chemotherapy expert consensus gastrointestinal complications hematopoietic stem cell transplantation intestinal microecology tumor treatment

SCI

English

Corresponding

Oncology

Oncology

WOS:000917364100001

WOLTERS KLUWER MEDKNOW PUBLICATIONS

Web of Science

1.Hongkong Univ, Shenzhen Hosp, Dept Hematol, Shenzhen, Peoples R China
2.Shandong First Med Univ, Affiliated Hosp 1, Dept Oncol, Jinan, Peoples R China
3.Shandong Prov Qianfoshan Hosp, Shandong Lung Canc Inst, Shandong Key Lab Rheumat Dis & Translat Med, Jinan, Peoples R China
4.Wuhan Univ Sci & Thchnol, Med Coll, Hubei Prov Key Lab Occupat Hazard Identificat & C, Inst Infect Immunol & Tumor Microenvironm, Wuhan, Peoples R China
5.Huazhong Univ Sci & Technol, Tongji Med Coll, Basic Med Sch, Dept Immunol, Wuhan, Peoples R China
6.Chinese Acad Sci, Inst Microbiol, Key Lab Pathogen Microbiol & Immunol, Beijing, Peoples R China
7.Chinese Univ Hong Kong, CUHK Shenzhen Res Inst, Inst Digest Dis, Li Ka Shing Inst Hlth Sci, Hong Kong, Peoples R China
8.Chinese Univ Hong Kong, CUHK Shenzhen Res Inst, Li Ka Shing Inst Hlth Sci, Dept Med & Therapeut,State Key Lab Digest Dis, Hong Kong, Peoples R China
9.Shenzhen Univ Hlth Sci Ctr, Shenzhen Univ Clin Med Acad, Shenzhen Univ Gen Hosp, Dept Hematol & Oncol,Int Canc Ctr,Shenzhen Key La, Xueyuan AVE 1098, Shenzhen, Peoples R China
10.Southern Univ Sci & Technol, Hosp 2, Shenzhen Peoples Hosp 3, Dept Oncol,Natl Clin Res Ctr Infect Dis, Shenzhen, Peoples R China
11.Fudan Univ, Dept Med Oncol, Pudong Med Ctr, Shanghai, Peoples R China
12.Peking Univ Canc Hosp & Inst, Minist Educ Beijing, Key Lab Carcinogenesis & Translat Res, Beijing, Peoples R China
13.Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Dept Thyroid & Breast Surg, Wuhan, Peoples R China
14.Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Inst Hematol, Wuhan, Peoples R China
15.Guangdong Prov Ctr Dis Control & Prevent, Guangdong Prov Inst Publ Hlth, Guangzhou, Peoples R China
16.Hubei Med Evaluat & Continuing Educ Off, Wuhan, Peoples R China
17.Shandong First Med Univ & Shandong Acad Med Sci, Jinan, Peoples R China
18.Nankai Univ, Coll Life Sci, Minist Educ, Key Lab Mol Microbiol & Technol, Tianjin, Peoples R China
19.Shanxi Univ, Sch Life Sci, Taiyuan, Peoples R China
20.Third Peoples Hosp Hubei Prov, Dept Anesthesiol, Wuhan, Peoples R China
21.Sun Yat Sen Univ Canc Ctr, Med Dept, State Key Lab Oncol South China, Guangzhou, Peoples R China
22.Hubei Maternal & Child Hlth Care Hosp, Wuhan, Peoples R China
23.Wuhan Univ, Dept Oncol, Renmin Hosp, Wuhan, Peoples R China
24.Capital Med Univ, Beijing Tongren Hosp, Dept Hematol, Beijing, Peoples R China
25.Huazhong Univ Sci & Technol, Coll Life Sci & Technol, Dept Biotechnol, Wuhan, Peoples R China
26.Huazhong Univ Sci & Technol, Tongji Med Coll, Hubei Canc Hosp, Dept Radiat Oncol, Wuhan, Peoples R China
27.Chinese Acad Med Sci & Peking Union Med Coll, Canc Hosp, Natl Canc Ctr, Natl Clin Res Canc Canc, Shenzhen, Peoples R China
28.Chinese Acad Med Sci & Peking Union Med Coll, Shenzhen Hosp, Shenzhen, Peoples R China
29.Tianjin Univ, Med Coll, Tianjin, Peoples R China
30.Soochow Univ, Affiliated Hosp 1, Dept Hematol, Suzhou, Peoples R China
31.Collaborat Innovat Ctr Hematol, Jiangsu Inst Hematol, Natl Clin Res Ctr Hematol Dis, Suzhou, Peoples R China
32.Chinese Peoples Liberat Army Gen Hosp, Med Ctr 5, Dept Hematol, Beijing, Peoples R China
33.Wuhan Univ, Dept Hematol, Zhongnan Hosp, Wuhan, Peoples R China
34.Huazhong Univ Sci & Technol, Tongji Med Coll, Cent Hosp Wuhan, Dept Orthoped, Wuhan, Peoples R China
35.Sun Yat Sen Univ, Affiliated Hosp 7, Dept Hematol, Shenzhen, Peoples R China
36.Chongqing Univ Canc Hosp, Chongqing, Peoples R China
37.Southern Univ Sci & Technol, Hosp 2, Shenzhen Peoples Hosp 3, Natl Clin Res Ctr Infect Dis,Dept Hematol, Shenzhen, Peoples R China

Wang, Jun,Liang, Jing,He, Mingxin,et al. Chinese expert consensus on intestinal microecology and management of digestive tract complications related to tumor treatment (version 2022)[J]. Journal of Cancer Research and Therapeutics,2022,18(7).

Wang, Jun.,Liang, Jing.,He, Mingxin.,Xie, Qi.,Wu, Qingming.,...&Guo, Zhi.(2022).Chinese expert consensus on intestinal microecology and management of digestive tract complications related to tumor treatment (version 2022).Journal of Cancer Research and Therapeutics,18(7).

Wang, Jun,et al."Chinese expert consensus on intestinal microecology and management of digestive tract complications related to tumor treatment (version 2022)".Journal of Cancer Research and Therapeutics 18.7(2022).